FDA inspection
Suzhou Lixin Pharmaceutical Co. Ltd.: FDA inspection ending Aug 30, 2023
FDA inspection 1259886 · Voluntary Action Indicated (VAI) · Suzhou
Key facts
| Inspection ID | 1259886 |
|---|---|
| Firm | Suzhou Lixin Pharmaceutical Co. Ltd. |
| FEI number | 3008251350 |
| Address | 21 Tangxi Road |
| City | Suzhou |
| Country | China |
| Fiscal year | 2023 |
| Inspection end date | Aug 30, 2023 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data